M. Sostek

发表

Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers.

C. Gottfridsson, G. Carlson, J. Lappalainen, 2013, Clinical therapeutics.

A description of clinical characteristics and treatment patterns observed within prescribed opioid users in Germany and the UK.

M. Sostek, P. Chevalier, M. Smulders, 2014, Pain management.

Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams.

D. Johnson, J. Johanson, M. Sostek, 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Population Exposure‐Response Modeling of Naloxegol in Patients With Noncancer‐Related Pain and Opioid‐Induced Constipation

N. Al-Huniti, J. Lappalainen, M. Sostek, 2016, CPT: pharmacometrics & systems pharmacology.

Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients.

K. Bui, Hongmei Xu, N. Al-Huniti, 2016, British journal of clinical pharmacology.

Pharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation

K. Bui, E. Floettmann, M. Sostek, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Effects of CYP3A Modulators on the Pharmacokinetics of Naloxegol

Diansong Zhou, K. Bui, N. Al-Huniti, 2016, Journal of clinical pharmacology.

Treatment of Chronic Posterior Laryngitis With Esomeprazole

R. Shaker, J. Richter, M. Vaezi, 2006, The Laryngoscope.

Purification of a calcium-activated neutral proteinase from bovine brain

E. Hogan, M. Sostek, N. Banik, 1983, Neurochemical Research.

Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis

J. Johanson, M. Sostek, M. Fennerty, 2005, Alimentary pharmacology & therapeutics.

The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol

K. Bui, M. Sostek, F. She, 2014, Journal of clinical pharmacology.

A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: Results from two randomized, parallel-group, placebo-controlled trials

M. Hochberg, C. Hwang, M. Sostek, 2011, Annals of medicine.

Patient Preferences for Change in Symptoms Associated with Opioid-Induced Constipation

R. Epstein, M. Khalid, R. Aubert, 2014, Advances in Therapy.

The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol

K. Bui, M. Sostek, F. She, 2014, Journal of clinical pharmacology.

Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial.

S. Field, H. Nelson, M. Sostek, 2006, American journal of respiratory and critical care medicine.

When People with Opioid-Induced Constipation Speak: A Patient Survey

R. Epstein, J. Teagarden, M. Sostek, 2017, Advances in Therapy.

Pharmacokinetics and Relative Bioavailability of a Fixed‐Dose Combination of Enteric‐Coated Naproxen and Non‐Enteric‐Coated Esomeprazole Magnesium

M. Sostek, L. Wang-Smith, Ying Zhang, 2012, Journal of clinical pharmacology.

Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial.

R. Fass, M. Sostek, S. Sontag, 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Effects of Esomeprazole on Acid Output in Patients With Zollinger-Ellison Syndrome or Idiopathic Gastric Acid Hypersecretion

D. Metz, P. Ruszniewski, C. Forsmark, 2007, The American Journal of Gastroenterology.

Zollinger-Ellison Syndrome Successfully Treated with Esomeprazole

M. Sostek, F. Troiano, 2003 .

The effect of quinidine, a strong P‐glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol

Diansong Zhou, K. Bui, N. Al-Huniti, 2016, Journal of clinical pharmacology.

Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects

M. Hutchison, K. Bui, M. Sostek, 2015, International journal of clinical pharmacology and therapeutics.

Intragastric acid suppression and pharmacokinetics of twice‐daily esomeprazole: a randomized, three‐way crossover study

T. Andersson, D. O. Castell, D. Castell, 2004, Alimentary pharmacology & therapeutics.

Description of Cardiovascular Event Rates in Patients Initiating Chronic Opioid Therapy for Noncancer Pain in Observational Cohort Studies in the US, UK, and Germany

M. Sostek, P. Chevalier, S. Chavoshi, 2014, Advances in Therapy.

Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending‐dose study

K. Bui, M. Sostek, M. Eldon, 2015, Clinical pharmacology in drug development.

A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation

L. Webster, J. Lappalainen, M. Sostek, 2013, PAIN®.

Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study

Yusong Chen, M. Sostek, P. Katz, 2003, American Journal of Gastroenterology.

Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers

M. Sostek, J. Fort, L. Estborn, 2011, Current medical research and opinion.

Randomised clinical trial: the long‐term safety and tolerability of naloxegol in patients with pain and opioid‐induced constipation

W. Chey, L. Webster, J. Tack, 2014, Alimentary pharmacology & therapeutics.

Naloxegol for opioid-induced constipation in patients with noncancer pain.

W. Chey, L. Webster, J. Tack, 2014, The New England journal of medicine.

Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults

J. Pisegna, M. Sostek, P. Miner, 2007, Alimentary pharmacology & therapeutics.

Clinical trial: the incidence of NSAID‐associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric‐coated naproxen alone

M. Hochberg, C. Hwang, M. Sostek, 2010, Alimentary pharmacology & therapeutics.

Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole.

T. Andersson, Yusong Chen, M. Sostek, 2007, British journal of clinical pharmacology.

Reanalysis of Intragastric pH Results Based on Updated Correction Factors for Slimline® and Zinetics™ 24 Single-Use pH Catheters

Yusong Chen, M. Sostek, P. Katz, 2006, The American Journal of Gastroenterology.

Comparison of the effects of intravenously and orally administered esomeprazole on acid output in patients with symptoms of gastro‐oesophageal reflux disease

D. Metz, M. Sostek, D. Heuman, 2005, Alimentary Pharmacology and Therapeutics.

High prevalence of chronic gastrointestinal symptoms in a National Guard Unit of Persian Gulf veterans.

E. Schimmel, M. Sostek, B. G. Fincke, 1996, The American journal of gastroenterology.

Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response

J. Tack, J. Lappalainen, M. Sostek, 2015, United European gastroenterology journal.

Treatment patterns, healthcare utilization, and costs of chronic opioid treatment for non-cancer pain in the United States.

M. Sostek, S. Chavoshi, R. LoCasale, 2015, The American journal of managed care.

Duodenal obstruction by abdominal aortic aneurysm.

M. Sostek, S. Fine, T. L. Harris, 1993, The American journal of medicine.

Focus of signet ring cell carcinoma in an adenoma of the sigmoid colon.

M. Sostek, M. Klein, M. Tandon, 1999, Archives of Pathology & Laboratory Medicine.

Delivery of esomeprazole magnesium enteric-coated pellets through small caliber and standard nasogastric tubes and gastrostomy tubes in vitro.

C. White, M. Sostek, J. Kalus, 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.

D. Angiolillo, C. Hwang, M. Sostek, 2011, Clinical therapeutics.

Ca2+ -mediated degradation of central nervous system (CNS) proteins: Topographic and species variation

E. Hogan, M. Sostek, N. Banik, 1987, Metabolic Brain Disease.

Efficacy of Naloxegol in a Subpopulation of Patients with Opioid-induced Constipation and an Inadequate Baseline Response to Laxatives: Results from Two Prospective, Randomized Controlled Trials: 1884

W. Chey, L. Webster, J. Tack, 2013 .

900 Efficacy and Safety of Naloxegol in Patients With Opioid-Induced Constipation: Results From 2 Prospective, Randomized, Controlled Trials

W. Chey, L. Webster, J. Tack, 2013 .

Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis

G. Ginsberg, D. Silberg, M. Sostek, 2006, Alimentary pharmacology & therapeutics.

Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.

D. Castell, R. Tutuian, M. Sostek, 2006, Clinical therapeutics.